Psilocybin
News You Might Have Missed: Dec 5th 2022
The article News You Might Have Missed: Dec 5th 2022 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup…
The article News You Might Have Missed: Dec 5th 2022 was originally published on Microdose.
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Protests in Ottawa for Access to Psychedelic Medicine
Non-profit group TheraPsil has brought a group of patients and medical professionals across Canada to Ottawa to fight for medical access to psilocybin mushrooms.
The intent is to engage with policymakers and the public around well-established potential benefits of psilocybin for end-of-life anxiety, depression and PTSD. A protest was held at 1 pm on Nov 29th and 30th, 2022, at Parliament Hill in Ottawa.
DEA Increases Production Quotas for Psychedelics
The Drug Enforcement Administration (DEA) has released its production quotas for 2023, announcing an increase in the permitted quantity of psychedelic compounds manufactured for research purposes. This is good news, as the increase will make it that much easier for researchers to continue their work.
Numinus Wellness Reports Q4 2022 and Annual Results
“Fiscal 2022 was a pivotal year for Numinus, as we entered the US market with the transformational acquisition of Novamind, expanded our Ketamine-assisted Therapy offering across Canada, launched a formal practitioner training program, and unveiled a global rebranding of our company.” Payton Nyquvest, Founder and CEO.
- Q4 2022 revenues grew 643% year-over-year to $4.2 million
- Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profit
- Completed acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapies
- Ended quarter with cash position of $33.0 million
New Study Shows Psychedelics Lowers Barriers to Higher Brain States
A new study shows that psychedelics lower the energy needed to reach higher levels of consciousness. A recent study conducted by Cornell University has shown that psychedelics might lower the energy threshold brain networks require in order to shift to different configurations. How is this possible? The theories and models surrounding such findings are going to be illustrated in this article, which also provides an outline of the results of the study.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
psilocybin ketamine psychedelic therapy depression anxiety ptsd psychedelics novamind numinus wellness numinus research
-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation7 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights